



(M24)

Attorney Docket No. 08841.105022 (PHARM1030US)

040
03/25/02
1614

1611 (2)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Stuyver *et al.*

Serial No.: 10/023,637

Filed: December 17, 2001

For: Antiviral Agents for Treatment of Flaviviridae Infections

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Assistant Commissioner for Patents
Washington, DC 20231

March 21, 2002

RECEIVED
AUG 02 2002
TECH CENTER 1600/2900

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publication listed on the accompanying Form PTO-1449A. A copy of the listed reference is enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,

Josephine Young
Registration No. 48,308

RECEIVED
AUG 02 2002
TECH CENTER 1600/2900

KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-4600 (Telephone)
404-572-5145 (Facsimile)

RECEIVED


AUG 02 2002

TECH CENTER 1600/2900




CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


Josephine Young

Date: March 21, 2002

Please type a plus sign (+) inside this box → 

PTO/SO/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known	
Application Number	10/023,637
Filing Date	December 17, 2001
First Named Inventor	Stuyver <i>et al.</i>
Group Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	PHAR1030US

RECEIVED
AUG 02 2002
TECH CENTER 1600/2900

Sheet **1** of **1**

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	4,686,234		Nelson <i>et al.</i>	08-11-1987	
	AB	5,026,687		Yarchoan <i>et al.</i>	06-25-1991	
	AC	5,496,546		Wang <i>et al.</i>	03-05-1996	
	AD	5,633,388		Diana <i>et al.</i>	05-27-1997	
	AE	5,665,728		Morris <i>et al.</i>	09-09-1997	
	AF	5,830,905		Diana <i>et al.</i>	11-03-1998	
	AG	5,846,964		Ozeki <i>et al.</i>	12-08-1998	
	AH	5,891,874		Colacino <i>et al.</i>	04-06-1999	
	AI	5,922,757		Chojkier <i>et al.</i>	07-13-1999	
	AJ	6,034,134		Gold <i>et al.</i>	03-07-2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Office ³	Number	Kind Code ² (if known)				
	AK	WO	95/22538		Artis, D.R. <i>et al.</i>	24-08-1995		
	AL	WO	97/38689		Haerberlin, B. <i>et al.</i>	23-10-1997		
	AM	WO	98/15563		Pankiewicz <i>et al.</i>	16-04-1998		
	AN	WO	00/33876		Lindner, J., <i>et al.</i>	15-06-2000		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → □

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

MAR 26 2002

U.S. PATENT & TRADEMARK OFFICE

Complete if Known

Application Number 10/023,637
 Filing Date December 17, 2001
 First Named Inventor Stuyver *et al.*
 Group Art Unit N/A
 Examiner Name N/A
 Attorney Docket Number PHAR1030US

RECEIVED

AUG 02 2002

TECH CENTER 1600/2900

Sheet 2 of 123

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	BA	BATTAGLIA, A.M. <i>et al.</i> "Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection." <i>Ann. Pharmacother.</i> 34:487-494, April 2000.	
	BB	BERENGUER, M. <i>et al.</i> "Hepatitis C virus in the transplant setting." <i>Antivir. Ther.</i> 3 (Suppl. 3):125-136, 1998.	
	BC	BULLINGHAM, R.E.S., <i>et al.</i> "Pharmacokinetics of Mycophenolate Mofetil (RS61443): A Short Review." <i>Transplant. Proc.</i> 28(2):925-929, April 1996.	
	BD	COLBY, T.D., <i>et al.</i> "Crystal structure of human type II inosine monophosphate dehydrogenase: Implications for ligand binding and drug design." <i>Proc. Nat. Acad. Sci. USA.</i> 96:3531-3536, March 1999.	
	BE	FRANKLIN, T.J., <i>et al.</i> "Human Colorectal Carcinoma Cell In Vitro as a Means to Assess the Metabolism of Analogs of Mycophenolic Acid." <i>Drug Metabolism and Disposition.</i> 25(3):367-370, 1997.	
	BF	HALE, M.D., <i>et al.</i> "The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation." <i>Clin. Pharmacol. & Ther.</i> 64(6):672-683, December 1998.	
	BG	JONES, D.F., <i>et al.</i> "Preparation and Antitumor Properties of Analogs and Derivatives of Mycophenolic Acid." <i>J. Med. Chem.</i> 14(4):305-311, 1971.	
	BH	KABAT, M.M., <i>et al.</i> "Synthesis of 5- β -D-Ribofuranosyl nicotinamide and Its N-Methyl Derivative. The Isoelectric and Isoelectronic Analogues of Nicotinamide Nucleoside ¹ ." <i>J. Med. Chem.</i> 30:924-927, 1987.	
	BI	NELSON, P.H., <i>et al.</i> "Structure-Activity Relationships for Inhibition of Inosine Monophosphate Dehydrogenase by Nuclear Variants of Mycophenolic Acid." <i>J. Med. Chem.</i> 39:4181-4196, 1996.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTOSB08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

MAR 26 2002

Complete if Known

Application Number 10/023,637
Filing Date December 17, 2001
First Named Inventor Stuyver et al.
Group Art Unit N/A
Examiner Name N/A
Attorney Docket Number PHAR1030US

RECEIVED
AUG 02 2002
TECH CENTER 1600, 2900

Sheet 3 of

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	CA	NELSON, P.H., et al. "Synthesis and Immunosuppressive Activity of Some Side-Chain Variants of Mycophenolic Acid." <i>J. Med. Chem.</i> 33:833-838, 1990.	
	CB	PANKIEWICZ, et al. "Efficient Synthesis of 5-(β-D-Ribofuranosyl) nicotinamide and Its α-Isomer ¹ ." <i>J. Org. Chem.</i> 53(15):3473-3479, 1988.	
	CC	PRAJDA, N., et al. "Sequential Impact of Tiazofurin and Ribavirin on the Enzymic Program of the Bone Marrow." <i>Cancer Res.</i> 53(24):5982-5986, December 15, 1993.	
	CD	SCHMOUDER, R., et al. "Pharmacokinetics of ERL080A: A New Enteric Coated Formulation of Mycophenolic Acid-Sodium." <i>Transplantation.</i> 67(Suppl.):S203, 1999.	
	CE	SHAW, L.M., et al. "Mycophenolate Mofetil: A Report of the Consensus Panel." <i>Ther. Drug Monit.</i> 17(6):690-699, December 1995.	
	CF	SINTCHAK, M.D., et al. "Structure and Mechanism of Inosine Monophosphate Dehydrogenase in Complex with the Immunosuppressant Mycophenolic Acid." <i>Cell.</i> 85(6):921-930, June 14, 1996.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.